Hypolipidaemia is not always indicating liver dysfunction. A review of primary and secondary high density lipoprotein and low density lipoprotein deficiencies

Minerva Medica

Volumn 97, Issue 6, 2006, Pages 487-494

  Andrikoula, M ^a,c   Avades, T ^b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c NONE   (Greece)

Author keywords

Apolipoproteins; Cholesterol; Hepatitis C; Lecithin cholesterol acyltransferase; Triglycerides

Indexed keywords

ABC TRANSPORTER A1; ANDROGEN; APOLIPOPROTEIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; THIAZIDE DIURETIC AGENT; TOXIC SUBSTANCE; TRIACYLGLYCEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ANEMIA; CHOLESTASIS; CHRONIC DIARRHEA; COLON CARCINOMA; DIABETES MELLITUS; DRUG INDUCED DISEASE; ENDOCRINE DISEASE; GENE MUTATION; HEPATITIS C; HUMAN; HYPERTHYROIDISM; HYPOALPHALIPOPROTEINEMIA; HYPOBETALIPOPROTEINEMIA; HYPOCHOLESTEROLEMIA; HYPOLIPEMIA; HYPOPITUITARISM; HYPOTHYROIDISM; IMMOBILIZATION; INFLAMMATION; KIDNEY CARCINOMA; LECITHIN CHOLESTEROL ACYLTRANSFERASE DEFICIENCY; LIVER DYSFUNCTION; MALABSORPTION; MALARIA; MALNUTRITION; MELANOMA; MYELOPROLIFERATIVE DISORDER; RECTUM CANCER; REVIEW; SMOKING; TANGIER DISEASE; UREMIA; DYSLIPIDEMIA; LIVER DISEASE;

CHOLESTEROL, HDL; CHOLESTEROL, LDL; DYSLIPIDEMIAS; HUMANS; LIVER DISEASES;

EID: 33847786461     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Durrington P. Lipoproteins and their metabolism. In: Durrington P editor. Hyperlipidaemia. Diagnosis and Management. Oxford: Butterworth and Co. Ltd; 1989. p. 23-55.
2. Dixon JL, Ginsberg HN. Hepatic synthesis of lipoproteins and apolipoproteins. Semin Liver Dis 1992;12:,364-72.
3. Crippin JS, Lindor KD, Jorgensen R, Kottke BA, Harrison JM, Murtaugh PA et al. Hypercholesterolemia in primary biliary cirrhosis: what is the risk? Hepatology 1992;15:858-62.
4. Cooper AD, Ellsworth JL. Lipoprotein metabolism. In: Zakim D, Boyer TD editors. Hepatology - A textbook of liver diseases. Philadelphia: Saunders; 1996. p. 92-130.
5. Kayden HJ. Abetalipoproteinaemia. Ann Rev Med 1972;28:285-96.
6. Whitfield AJ. Barrett HR, Robertson K, Havlat MF, van Bockxmeer FM. Burnett JR et al. Liver dysfunction and steatosis in familial hypobetalipoproteinaemia. Clin Chem 2005;51:266-9.
7. Miller M, Zhan M. Genetic determinants of low high density lipoprotein cholesterol. Curr Opin Cardiol 2004;19:380-4.
8. Pisciotta L, Hamilton-Craig I, Tarugi P, Bellocchio A, Fasano T, Alessandrini P et al. Familial HDL deficiency due to ABCA1 gene mutations with or without other genetic lipoprotein disorders. Atherosclerosis 2004;172:309-20.
9. Probst MC, Thumann H, Aslanidis C, Langmann T, Buechler C, Patsch W et al. Screening for functional sequence variations and mutations in ABCA1. Atherosclerosis 2004;175:269-79.
10. Havel RJ, Goldstein JL, Brown MS. Lipoproteins and lipid transport. In: Bondy PK, Rosenberg LE editors. Metabolic control and disease. 8th ed. Philadelphia: WB Saunders Co; 1980. p. 393.
11. Herbert PN, Gotto AM, Fredrickson DS. Familial lipoprotein deficiency (abetalipoproteinaemia, hypobetalipoproteinaemia and Tangier disease). In: Stanbury JB, Wyngaarden JB, Fredrickson DS editors. The metabolic basis of inherited disease. 4th ed. New York: McGraw-Hill Book Co; 1978. p. 544.
12. Assmann G, Herbert PN, Fredrickson DS, Forte T. Isolation and characterization of an abnormal high density lipoprotein in Tangier disease. J Clin Invest 1977;60:242-52.
13. Assmann G, Simantke O, Schaefer HE, Smootz E. Characterization of high density lipoproteins in patients heterozygous for Tangier disease. J Clin Invest 1977;60:1025-35.
14. Hovingh GK, Kuivenhoven JA, Bisoendial RJ, Groen AK, van Dam M, van Tol A et al. HDL deficiency and atherosclerosis: lessons from Tangier disease. J Int Med 2004;255:299-301.
15. Franceschini G, Sirtori CR, Capurso A 2nd, Weisgraber KH, Mahley RW. ApoA1-Milano apoprotein. Decreased high density lipoprotein cholesterol levels with significant lipoprotein modifications and without clinical atherosclerosis in an Italian family. J Clin Invest 1980;66:892-900.
16. Vigushin DM, Gough J, Allan D, Alguacil A, Penner B, Pettigrew NM et al. Familial nephropathy systemic amyloidosis caused by apolipoprotein A1 variant Arg26. Q J Med 1994;87:149-54.
17. Booth DR, Tan SY, Booth SE, Tennent GA, Hutchinson WL, Hsuan JJ et al. Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein A1 gene. J Clin Invest 1996;97:2714-21.
18. Gjone E, Norum KR, Glomset JA. Familial lecithin: cholesterol acyltransferase deficinency. In: Stanbury JB, Wyngaarden JB, Fredrickson DS editors. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill; 1978. p. 589.
19. Gjone E. Familial lecithin: cholesterol acyltransferase deficiency: a clinical survey. Scand J Clin Lab Invest 1974;33 Suppl 137:73-82.
20. Carlson LA, Philipson B. Fish-eye disease: a new familial condition with massive corneal opacities and dyslipoproteinaemia. Lancet 1979;8149:922-4.
21. Crook MA, Velauthar U, Moran L, Griffiths W. Hypocholesterolaemia in a hospital population. Ann Clin Biochem 1999;36:613-6.
22. Levesque H, Gancel A, Pertuet S, Czemichow P, Courtois H. Hypocholesterolaemia, prevalence, diagnostic and prognostic significance. Presse Med 1991;20:1935-8.
23. Oster P, Muchowski H, Heuck CC, Schlierf G. The prognostic significance of hypocholesterolaemia in hospitalized patients. Klin Wochenschr 1981;59:857-60.
24. Forette B, Tortrat D, Wolmark Y. Cholesterol is a risk factor for mortality in elderly women. Lancet 1989;8643:868-70.
25. Verdery RB, Goldberg AP. Hypocholesterolaemia as a predictor of death: a prospective study of 224 nursing home residents. J Gerontol 1991;46:84-90.
26. Noel MA, Smith TK, Ettinger WH. Characteristics and outcomes of hospitalized older patients who develop hypocholesterolaemia. J Am Geriatr Soc 1991;39:455-61.
27. Rudman D, Mattson DE, Nagraj HS, Feller AG, Jackson DL, Caindec N et al. Prognostic significance of serum cholesterol in nursing home men. Scand J Clin Lab Invest 1988;12:155-8.
28. Lee WM. Acute liver failure. N Engl J Med 1993;329:1862-72.
29. Tietge UJF, Boker KHW, Bahr MJ, Weinberg S, Pichlmayr R, Schmidt HH et al. Lipid parameters predicting liver function in patients with cirrhosis and after liver transplantation. Hepatogastroenterology 1998;45:2255-60.
30. Nayak SS, Ramani A, Kamath SS, Kundaje GN, Aroor AR. Serum apoproteins A and B and the lecithin: cholesterol acyl transferase activities in liver cirrhosis and hepatic coma patients. Biochem Med Metab Biol 1988;40:299-304.
31. Camps J, Pizarro I, Prats E, La Ville A, Turner PR, Masana L et al. Plasma lipoprotein alterations in patients with chronic hepatocellular liver disease resulting form alcohol abuse:effects of alcohol intake cessation. J Hepatol 1994;21:704-9.
32. Cicognani C, Malavolti M, Morselli-Labate AM, Zamboni L, Sama C, Barbara L. Serum lipid and lipoprotein patterns in patients with liver cirrhosis and chronic active hepatitis. Arch Intern Med 1997;157:792-6.
33. D'Arienzo A, Manguso F, Scaglione G, Vicinanza G, Bennato R, Mazzacca G. Prognostic value of progressive decrease in serum cholesterol in predicting survival in Child-Pugh C viral cirrhosis. Scand J Gastroenterol 1998;33:1213-8.
34. Zoli M, Cordianai MR, Marchesini G, Iervese T, Labate AM, Bonazzi C et al. Prognostic indicators in compensated cirrhosis. Am J Gastroenterol 1991;86:1508-13.
35. Maggi G, Bottelli D, Gola D, Perricone G, Pesca M, Zavaglia C et al. Serum cholesterol and chronic hepatitis C. Ital J Gastroenterol 1996;28:436-40.
36. Stapleton JT, Swindells S, Polgreen P. Hepatitis C virus infection is associated with a decreased risk of hypercholesterolaemia but not hyperglycaemia in HIV-infected people. International AIDS Conference, 2002, July 7-12, Barcelona, Spain.
37. Vuoristo M, Miettinen TA. Cholesterol absorption, elimination and synthesis in coeliac disease. Eur J Clin Invest 1982;12:285-91.
38. Westerman MP. Hypocholesterolaemia and anaemia. Br J Haematol 1975;31:87-94.
39. Lenzen S, Kucking H. Inhibition of insulin secretion by L-thyroxine and D-thyroxine treatment in rats. Acta Endocrinol 1982;100:527-33.
40. Lambrecht AJ, Snoeck J, Timmermans U. Transient an-alpha-lipoproteinaemia in man during infection by Plasmodium vivax. Lancet 1978;8075:1206.
41. Cabana VG, Siegel JN, Sabesin SM. Effects of acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res 1989;30:39-49.
42. Volpato S, Palmieri E, Fellin R, Zuliani G. Acute phase markers are associated with reduced plasma lipid levels in a population of hospitalised elderly patients. Gerontology 2000;46:22-7.
43. Dangler R, Lottspeich F, Oberthur W, Mast AE, Emmerich B. Limited proteolysis of alpha-1-proteinase inhibitor (alpha 1-PI) in acute leukaemia: studies on the resulting fragments and implication for the structure of the inactivated inhibitor. Biol Chem Hoppe Seyler 1995;376:165-72.
44. Janciauskiene S, Al Rayyes O, Floren CH, Eriksson S. Low density lipoprotein catabolism is enhanced by the cleaved form of alpha-1-antitrypsin. Scand J Clin Lab Invest 1997;57:325-35.
45. Miller JP, Thompson GR. Plasma cholesterol esterification in patients with secondary hypocholesterolaemia. Eur J Clin Invest 1973;3:401-6.
46. Vitols S. Uptake of low density lipoprotein by malignant cells: possible therapeutic applications. Cancer Cells 1991;3:488-95.
47. Vitols S, Gahrton G, Bjorkholm M, Peterson C. Hypocholesterolaemia in malignancy due to elevated low density lipoprotein receptor activity in tumour cells: evidence from studies in patients with leukaemia. Lancet 1985;8465:1150-4.
48. Gilbert HS, Ginsberg H, Fagerstrom R, Brown WV. Characterization of hypocholesterolaemia in myeloproliferative disease: relation to disease manifestation and activity. Am J Med 1981;71:595-602.
49. Winawer SJ, Flehinger BJ, Buchalter J, Herbert E, Shike M. Declining serum cholesterol levels prior to diagnosis of colon cancer. JAMA 1990;263:2083-5.
50. Muller CP, Trilling B, Steinke B. The prognostic significance of total serum cholesterol in patients with Hodgkin's disease. Cancer 1992;69:1042-6.
51. Marenah CB, Lewis B, Hassall D, La Ville A, Cortese C, Mitchell WD et al. Hypocholesterolaemia and non-cardiovascular disease in metabolic studies on subjects with low plasma cholesterol. Br Med J (Clin Res Ed) 1983;286:1603-6.
52. Hinnie J, O'Reilly DS. Hypocholesterolaemia in hairy cell leukaemia. BMJ 1995;311:1437-8.
53. Lam TK, Sol Y, Leung KW. Hypocholesterolaemia in juvenile chronic myeloid leukaemia. Eur J Haematol 1988;40:283.
54. Juliusson G, Vitols S, Liliemark J. Mechanisms behind hypocholesterolaemia in hairy cell leukaemia. BMJ 1995;311:27.
55. Nimer SD, Champlin RE, Golde DW. Senim cholesterol-lowering activity of granulocyte-macrophage colony-stimulating factor. JAMA 1988;260:3297-300.
56. Motoyoshi K, Takaku F. Serum cholesterol-lowering activity of human monocytic colony-stimulating factor. Lancet 1989;8658:326-7.
57. Rosenberg SA. Immunotherapy of patients with advanced cancer using interleukin-2 alone or in combination with lymphokine activated killer cells. In: DeVita VT, Hellman, Rosenberg SA editors. Important advances in oncology. Philadelphia: Lippincott; 1988. p. 217-57.
58. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987;316:889-97.
59. Malmendier CL, Lontie J-F, Sculier JP, Dubois DY. Modification of plasma lipids, lipoproteins and apolipoproteins in advanced cancer patients treated with recombinant interleukin-2 and autologous lymphokine activated killer cells. Atherosclerosis 1988;73:173-80.
60. Wilson DE, Birchfield GR, Hejazi JS, Ward JH, Samlowski WE. Hypocholesterolaemia in patients treated with recombinant interleukin-2: appearance of remnant-like lipoproteins. J Clin Oncol 1989;7:1573-7.
61. Rosenzweig IB, Wiebe DA, Hank JA, Albers JJ, Adolphson JL, Borden E et al. Effects of interleukin-2 (IL-2) on human plasma lipid, lipoprotein and C-reactive protein. Biotherapy 1990;2:193-8.
62. Ettinger WH, Varma VK, Sorci-Thomas M, Parks JS, Sigmon RC, Smith TK et al. Cytokines decrease apolipoprotein accumulation in medium from HePG2 cells. Arterioscler Thromb 1994;14:8-13.
63. Kwong LK, Ridinger DN, Bandhauer M, Ward JH, Samlowski WE, Iverius PH et al. Acute dylipoproteinaemia induced by interleukin-2: lecithin: cholesteryl acyltransferase, lipoprotein lipase and hepatic lipase deficiencies. J Clin Endocrinol Metab 1997;82:1572-81.
64. Lotze MT, Matory YL, Rayner AA, Ettinghausen SE, Vetto JT, Seipp CA et al. Clinical effects and toxicity of interieukin-2 in patients with cancer. Cancer 1986;58:2764-72.
65. Suzuki K, Hara M, Kitani A, Harigai M, Norioka K, Kondo K et al. Augmentation of LDL receptor activities on lymphocytes by interleukin-2 and anti-CD3 antibody: a flow cytometric analysis. Biochem Biophys Acta 1990;1042:352-8.
66. Ginsberg H, Goldberg IJ, Wang-Iverson P, Gitler E, Le NA, Gilbert HS et al. Increased catabolism of native and cyclohexanedione-modified low density lipoprotein in subjects with myeloproliferative diseases. Arteriosclerosis 1983;3:233-41.
67. Budd D, Ginsberg H. Hypocholesterolaemia and acute myelogenous leukaemia. Cancer 1986;58:1361-5.
68. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinaemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol 2001;34:428-34.
69. Petit JM, Benichou M, Duvillard L, Jooste V, Bour JB, Minello A et al. Hepatitis C virus-associated hypobetalipoproteinaemia is correlated with plasma viral load, steatosis and liver fibrosis. Am J Gastroenterol 2003;98:1150-4.
70. Fabris C, Federico E, Soardo G, Falleti E, Pirisi M. Blood lipids of patients with chronic hepatitis: Differences related to viral etiology. Clin Chem Acta 1997;261:159-61.
71. Moriya K, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Yotsuyanagi H et al. Serum lipid profile of patients with genotype lb hepatitis C viral infection in Japan. Hepatol Res 2003;25:371-6.
72. Hijikata M, Shimizu YK, Kato H, Iwamoto A, Shih JW, Alter HJ et al. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol 1993;67:1953-8.
73. Xiang J, Klinzman D, McLinden J, Schmidt WN, Laveque DR, Gish R et al. Characterization of hepatitis G virus (GB-C virus) particles: evidence for a nucleocapsid and expression of sequences upstream of the E1 protein. J Virol 1998;72:2738-44.
74. Prince AM, Huima-Byron T, Parker TS, Levine DM. Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins. J Viral Hepatol 1996;3:11-7.
75. Thomssen R, Bonk S, Propfe C, Heermann KH, Kochel HG, Uy A. Association of hepatitis C virus in human sera with beta-lipoproteins. Med Microbiol Immunol 1992;181:293-300.
76. Monazahian M, Kippenberger S, Mueller A, Seitz H, Bohme I, Grethe S et al. Binding of human lipoproteins (low, very low, high density lipoproteins) to recombinant envelope proteins of hepatitis C virus. Med Microbiol Immunol 2000;188:177-84.
77. Wunschmann S, Medh JD, Klinzmann D, Schmidt WN, Stapleton JT. Characterization of hepatitis virus C (HCV) and (HCV) E2 interactions with CD81 and the low density lipoprotein receptor. J Virol 2000;74:1055-62.
78. Andre P, Komurian-Pradel F, Deforges S, Perret M, Berland JL, Sodoyer M et al. Characterization of low-and very-low-density hepatitis C virus RNA-containing particles. J Virol 2002;76:6919-28.
79. Monazahian M, Bohme I, Bonk S, Koch A, Scholz C, Grethe S et al. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J Med Virol 1999;57:223-9.
80. Agnello V, Abel G, Elfahal M, Knight GB, Zhang OX. Hepatitis C virus and other flaviviridae viruses eneter cells via low density lipoprotein receptor. Proc Natl Acad Sci USA 1999;96:12766-71.
81. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831-7.
82. Shor-Posner G, Basit A, Lu Y, Cabrejos C, Chang J, Fletcher M et al. Hypocholesterolaemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 1993;94:515-9.
83. Grunfeld C, Pang M, Doerrler W, Shigenaga JK, Jensen P, Feingold KR. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045-52.
84. Polgreen PM, Fultz SL, Justice AC, Wagner JH, Diekema DJ, Rabeneck L et al. Association of hypocholesterolaemia with hepatitic C virus infection in HIV-infected people. HIV Med 2004;5:144-50.